Every 8-K that Nanoviricides (NNVC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NNVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNVC filings page.
NanoViricides, Inc. entered into a securities purchase agreement with a single investor for a registered direct offering, selling 2,416,339 shares of common stock at $1.53 per share and pre-funded warrants for 100,000 shares at $1.52999, together with common warrants to purchase 2,516,339 shares at an exercise price of $1.75.
The pre-funded warrants are immediately exercisable at $0.00001 per share, while the common warrants become exercisable six months after issuance and expire five and one-half years from that date. The offering closed on July 27, 2026, generating approximately $3.8 million in gross proceeds before fees, to be used for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions and other strategic purposes. The company agreed to a 60-day restriction on additional equity issuances (with limited exceptions), 30-day lock-ups for its chief executive officer and principal stockholder, and to file a resale registration for warrant shares within 30 days of closing, while paying a 7.0% placement fee and up to $50,000 of placement agent expenses.
NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC, permitting the company to issue and sell shares of its common stock from time to time in an “at the market” offering under its existing Form S-3 shelf registration statement. Sales, if any, may occur on the NYSE American or other trading markets, or in privately negotiated transactions with the company’s prior written consent, based on parameters set in placement notices.
The company will pay the sales agent a 2.0% commission on the aggregate gross proceeds from any stock sales. The Placement Shares will be issued under the registration statement and a prospectus supplement filed on July 17, 2026, and the program will terminate when all such shares are sold or the agreement is ended by either party. A legal opinion from Lucosky Brookman LLP on the validity of the Placement Shares is included as an exhibit.
NanoViricides, Inc. reported that its President and Executive Chairman, Dr. Anil R. Diwan, participated in the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, in a fireside chat with A.G.P. equity research analyst Dr. James Molloy.
During the discussion, Dr. Diwan described two antiviral drug candidates developed during COVID-19: NV-387, a broad-spectrum antiviral now entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo, and a backup candidate where remdesivir is encapsulated within NV-387 nanoviricide micelles as an oral formulation.
He explained that remdesivir has prior Ebola clinical trial and safety data, that NV-387 encapsulation is designed to protect remdesivir from rapid metabolism based on animal studies and a peer‑reviewed PLOS One publication, and that the company maintains both NV-387 alone and NV-387 with remdesivir as candidates the company expects could address the current Ebola Bundibugyo strain in DRC, subject to public health authorities’ decisions.
NanoViricides, Inc. entered into a registered direct offering with a single institutional investor, raising approximately $2.0 million in gross proceeds through common shares or pre-funded warrants plus accompanying common warrants. The securities were priced at $1.50 per share (or $1.49999 per pre-funded warrant), with warrants to purchase 1,333,334 shares at an exercise price of $1.75 per share.
The financing closed after effectiveness of the company’s Form S-3 shelf registration and includes a 30-day restriction on most new equity issuances, a 10-day pause on at-the-market sales, and a 30-day CEO lock-up. NanoViricides plans to use net proceeds for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions or other strategic purposes.
NanoViricides, Inc. (NNVC) reported the results of its 2025 Annual Meeting of Stockholders. A quorum was present, with 7,906,820 common shares and 838,025 Series A Convertible Preferred shares entitled to vote, representing approximately 61% of the company’s outstanding voting capital stock.
Stockholders re-elected Anil Diwan as a Class I Director, with 9,757,652 votes for, 173,096 against, and 48,971 abstentions. An advisory vote on the compensation of the named executive officers also passed, receiving 9,500,223 votes for, 420,374 against, and 59,122 abstentions. Stockholders further ratified the appointment of EisnerAmper, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 14,594,257 votes for, 194,416 against, and 60,051 abstentions.
NanoViricides, Inc. announced a capital raise combining a registered direct offering and a concurrent private placement. The company sold 1,970,000 registered shares at $1.68 and issued pre-funded warrants for 1,601,429 shares at $1.67999 with a $0.00001 exercise price, immediately exercisable. In the private placement, it issued Series A and Series B warrants for up to 3,571,429 shares each, exercisable six months after issuance at $1.75 (A, two-year term) and $2.00 (B, five-and-a-half-year term).
The transaction closed on November 12, 2025, generating approximately $6.0 million in gross proceeds before fees, to be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as placement agent for a 7.0% cash fee, plus up to $60,000 in expenses and $15,000 in non-accountable expenses. The company agreed to a 90-day restriction on new equity issuances and filings, a 180-day prohibition on variable rate transactions, and 90-day lock-ups by directors and officers.
NanoViricides, Inc. filed an 8-K disclosing several exhibit-level agreements that were furnished with the report. The filing lists extensions of employment agreements for Anil Diwan and Meeta Vyas, with Meeta Vyas’s extension effective July 1, 2025. It also furnishes credit-and-collateral documents dated September 23, 2025: an amendment to a line of credit, an open-ended promissory note, and an open-ended mortgage deed. The report is signed by Anil Diwan as President and Chairman and dated October 1, 2025.
The filing provides the existence and dates of these agreements but contains no financial tables, amounts, or detailed terms in the provided text. The exhibits indicate personnel continuity at the executive level and new or amended financing arrangements secured on September 23, 2025, but the document fragment does not disclose monetary values, interest rates, collateral descriptions, covenants, or counterparty names beyond what is listed.